

29. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain*. 2019;142(3):744-759. <https://doi.org/10.1093/brain/awz030>.
30. Rusz J, Hlavnicka J, Novotny M, et al. Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease. *Ann Neurol*. 2021;90(1):62-75. <https://doi.org/10.1002/ana.26085>.
31. Seibler P, Streubel-Gallasch L, Klein C. Combining Biomarkers with Genetics In Prodromal/Earliest Phase Parkinson's Disease. *J Parkinsons Dis*. 2024;14(s2):S345-S351. <https://doi.org/10.3233/JPD-240155>.
32. Schaeffer E, Yilmaz R, St Louis EK, et al. Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson's Disease: A Narrative Review. *J Parkinsons Dis*. 2024;14(s2):S307-S319. <https://doi.org/10.3233/JPD-230428>.
33. Schalkamp AK, Peall KJ, Harrison NA, et al. Wearable movement-tracking data identify Parkinson's disease years before clinical diagnosis. *Nat Med*. 2023;29(8):2048-2056. <https://doi.org/10.1038/s41591-023-02440-2>.
34. Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. *Lancet Neurol*. 2023;22(5):407-417. [https://doi.org/10.1016/S1474-4422\(23\)00109-6](https://doi.org/10.1016/S1474-4422(23)00109-6).
35. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. *Lancet Neurol*. 2024;23(2):178-190. [https://doi.org/10.1016/S1474-4422\(23\)00405-2](https://doi.org/10.1016/S1474-4422(23)00405-2).
36. Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure: Predictors of conversion to clinical CNS involvement. *Neurology*. 2017;88(12):1129-1136. <https://doi.org/10.1212/WNL.0000000000003737>.
37. Sixel-Doring F, Muntean ML, Petersone D, et al. The Increasing Prevalence of REM Sleep Behavior Disorder with Parkinson's Disease Progression: A Polysomnography-Supported Study. *Mov Disord Clin Pract*. 2023;10(12):1769-1776. <https://doi.org/10.1002/mdc3.13908>.
38. Yoo HS, Chung SJ, Lee YH, et al. Olfactory anosmia is a predictor of cognitive decline and dementia conversion in Parkinson's disease. *J Neurol*. 2019;266(7):1601-1610. <https://doi.org/10.1007/s00415-019-09297-x>.
39. Zitser J, During EH, Chiaro G, et al. Autonomic impairment as a potential biomarker in idiopathic REM-sleep-behavior disorder. *Auton Neurosci*. 2019;220:102553. <https://doi.org/10.1016/j.autneu.2019.05.005>.

ON-LINE KURZ

On-line kurz
pro praktické neurology1
2025

OBSAH KURZU

- ▶ Revidovaná McDonaldova kritéria 2024 – doc. MUDr. Jana Lízrová Preiningerová, Ph.D.
- ▶ Význam sběru dat z klinické praxe – real-world evidence – zaměřeno na bezpečnost – prof. Helmut Butzkueven, MBBS, FRACP, PhD
- ▶ Perorální kladribin – nová data z observačních studií prezentovaná na kongrese ECTRIMS 2024 – doc. MUDr. Pavel Hradílek, Ph.D.
- ▶ Jak sbíráme data v České republice – národní registr ReMuS prof. MUDr. Dana Horáková, Ph.D.

ODBOBNÝ GARANT:

prof. MUDr. Eva Kubala Havrdová, CSc.
Neurologická klinika 1. LF UK a VFN v Praze

POŘADATEL:

SOLEN, s. r. o., ve spolupráci
s Neurologickou klinikou 1. LF UK a VFN v Praze

POČET
KREDITŮ 2Registrace
ZDARMA

TERMÍN
duben 2025
až březen 2026
dostupný na
online.solen.cz

ZLATÝ
PARTNER

MERCK

